Management of Patients With Rheumatoid Arthritis
Source: Rheumatology in Practice

Module

In this resource, Jasvinder Singh, MD, MPH, reviews optimal management of patients with RA in accordance with ACR and EULAR recommendations, including:
  • Drug indications in early vs established disease
  • Monitoring for adverse events
  • Treatment strategies in high-risk populations

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply clinical guideline treatment algorithms into therapy decisions to optimize care for patients with rheumatoid arthritis
  • Integrate current guidelines for monitoring patients for adverse events to control toxicity associated with rheumatoid arthritis therapies
  • Apply current guidelines into treatment to improve outcomes of patients with high-risk comorbid conditions and rheumatoid arthritis
Topics covered include:
  • RA Treatment
  • Monitoring for Adverse Events
  • Treatment in Patients With High-Risk Comorbidities
  • Contraindications for RA Therapy
  • Vaccination Recommendations in Patients With RA
 

Faculty

  • Jasvinder Singh
    MD, MPH

Credit Information

  • Release Date:
    November 03, 2016
  • Expiration Date:
    November 02, 2017
  • Physicians:
    maximum of 0.5 AMA PRA Category 1 Credits

Information on this Educational Activity

Disclosure of Conflicts of Interest

Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Faculty

Jasvinder Singh, MD, MPH


Professor of Medicine and Epidemiology
Division of Rheumatology
Department of Medicine
University of Alabama at Birmingham
Staff Physician
Birmingham VA Medical Center
Staff Rheumatologist
The Kirklin Clinic
Birmingham, Alabama

Jasvinder Singh, MD, MPH, has disclosed that he has received funds for research support from Savient and Takeda and consulting fees from Allergan, Ardea, Novartis, Regeneron, Savient, Takeda, and URL Pharmaceuticals.

 

Staff

Zachary Schwartz, MSc, ELS


Managing Editor

Zachary Schwartz, MSc, ELS, has nothing to disclose with regard to commercial interests.

 

Heather Stieglitz, PhD


Editorial Contributor

Heather Stieglitz, PhD, has nothing to disclose with regard to commercial interests.

 

Alyce Kuklinski, NP, RN


General Manager, Virology & Other Therapeutic Specialties

Alyce Kuklinski, NP, RN, has nothing to disclose with regard to commercial interests.

 

Disclaimer
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.

 

Target Audience

This activity is intended for physicians and other healthcare professionals involved in the medical management of patients with rheumatologic conditions.


Goal

The goal of this activity is to improve the knowledge and competence of physicians and other healthcare providers for the prevention, diagnosis, and treatment of patients with rheumatologic conditions.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply clinical guideline treatment algorithms into therapy decisions to optimize care for patients with rheumatoid arthritis
  • Integrate current guidelines for monitoring patients for adverse events to control toxicity associated with rheumatoid arthritis therapies
  • Apply current guidelines into treatment to improve outcomes of patients with high-risk comorbid conditions and rheumatoid arthritis
 

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Clinical Care Options, LLC. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Boston University School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by educational grants from Genentech, and Lilly USA, LLC..

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 03, 2016, through November 02, 2017:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

  • Tapering Therapy in Rheumatoid Arthritis: My Approach

    Eric M. Ruderman MD - 7/14/2016    3 comments / Last Comment: 12/15/2016
    Consideration of tapering RA therapy is a careful balance between sustained remission and drug tolerability. Here is my take on determining when it is appropriate and which agents to taper.
  • Biosimilars: Addressing Uncertainties With a New Drug Class

    Kenneth G. Saag MD, MSc - 3/13/2017    2 comments / Last Comment: 4/24/2017
    Biosimilars promise increased access and decreased prices for patients in need of expensive biologics. However, as with any new category of drug, biosimilars face some uncertainties. Here’s my take.
  • Key Considerations for Using Biosimilars in IBD

    David T. Rubin MD - 6/6/2017    1 comment / Last Comment: 6/22/2017
    The role of biosimilars in the setting of IBD is growing. Here’s my take on some of the key things you need to consider when using these agents.
  • The End of Winter or a False Spring? Introduction of Biosimilars in a Rheumatology Practice

    William F. C. Rigby MD - 6/12/2017    
    What does the availability of biosimilar products mean in your approach to rheumatologic conditions?
  • JAK Inhibitors in Rheumatoid Arthritis: Weighing the Anticipated Options

    Roy Fleischmann MD - 9/9/2016    1 comment / Last Comment: 12/15/2016
    Clinical trial data to date have shown tofacitinib and baricitinib to be largely similar in efficacy and safety. But are there meaningful differences that might help clinicians choose between them? Here’s my take.